
Urologist Evaluates Implications of the Removal of Flawed SEER PSA Data
Large data sets like SEER need better quality control checks and researchers and clinicians who use these data sets should also consider using secondary data analyses that answer specific research questions. This is the advice of a senior urologist following the removal of the PSA data.
A recent quality control check by the National Cancer institute (NCI) of the Surveillance, Epidemiology and End Results (SEER) and SEER-Medicare programs found that a significant number of these values were incorrect. Subsequently, NCI removed these PSA values from the data sets. A urologist at Vanderbilt University, David F. Penson, MD, MPH, has contributed an editorial in
Read the report on ScienceDaily:
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.